CURE Magazine

1 week ago | curetoday.com | Alex Biese

Antihistamines are associated with improvements in progression-free events and survival outcomes for patients with metastatic urothelial carcinoma (mUC) receiving Tecentriq (atezolizumab), research has shown. Drawing on data from 896 patients from the phase 2 IMvigor210 trial and phase 3 IMvigor211 trial, researchers published their findings in Urologic Oncology: Seminars and Original Investigations.

1 week ago | curetoday.com | Kristie Kahl

Precision medicine has revolutionized the treatment of prostate cancer, in particular the use of genetic testing for specific DNA damage repair genes to determine which patients would benefit from treatment with PARP inhibitors. Therefore, understanding these advancements is crucial for patients, as they offer more personalized and effective treatment strategies. “[Treatment is] not one-size-fits-all when it comes to managing patients with prostate cancer.

2 weeks ago | curetoday.com | Ariana Pelosci

In an assessment of more than 170,000 patients, GLP-1 drugs were not linked with higher cancer rates, and led to a decrease in obesity-related cancers and deaths, according to a study presented during the 2025 American Society of Clinical Oncology Annual Meeting. There was a 7% decrease in obesity-related cancer among patients who used GLP-1 receptor agonists with 2501 events vs 2671 events in patients who were DPP-4 users. For females, events observed were 1754 for GLP-1 and 1898 for DPP-4.

2 weeks ago | curetoday.com | Kristie Kahl

Understanding one’s treatment options is a crucial first step in making informed decisions about care. When the cancer is contained within the prostate gland, meaning it hasn't spread to other parts of the body, localized treatments are often the primary approach. Two key categories of localized treatment are surgery and focal therapy. Surgery, typically a radical prostatectomy, involves the complete removal of the prostate gland.

2 weeks ago | curetoday.com | Alex Biese

What is life like for someone after cancer? “Often it’s a series of physical adjustments,” Dr. Kevin Billingsley, surgical oncologist and chief medical officer at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, told CURE.